Search results for " Neoadjuvant Therapy"

showing 6 items of 16 documents

Minimally invasive interval debulking surgery in ovarian neoplasm (MISSION trial–NCT02324595): a feasibility study

2016

Background Laparoscopy has acquired an increasing role in the management of ovarian cancer. Laparoscopic cytoreduction could represent a new frontier for selected patients after neoadjuvant chemotherapy (NACT). Objective We sought to assess feasibility and early complication rate of minimally invasive (MI) interval debulking surgery (IDS) in stage III-IV epithelial ovarian cancer (EOC) patients after NACT. Study Design This is a phase II multicentric study in advanced EOC cases with clinical complete response after NACT, according to Gynecologic Cancer Intergroup and Response Evaluation Criteria In Solid Tumors criteria. Institutional review board approval was obtained and all patients sign…

Neoplasm Residualmedicine.medical_treatmentchemotherapyresidual0302 clinical medicine80 and overMedicineminimally invasive surgeryAged 80 and overOvarian Neoplasms030219 obstetrics & reproductive medicineadvanced ovarian cancerMedicine (all)Obstetrics and GynecologyCytoreduction Surgical ProceduresBowel resectionMiddle AgedDebulkinglaparoscopic cytoreductionNeoadjuvant TherapyIntestinesChemotherapy AdjuvantResponse Evaluation Criteria in Solid Tumors030220 oncology & carcinogenesisinterval debulking surgeryFemaleMedian bodyPeritoneumOmentumneoadjuvant chemotherapyAdultmedicine.medical_specialtyOvariectomyadvanced ovarian cancer; interval debulking surgery; laparoscopic cytoreduction; minimally invasive surgery; neoadjuvant chemotherapy; quality of life; Adult; Aged; Aged 80 and over; Appendectomy; Chemotherapy Adjuvant; Fallopian Tubes; Feasibility Studies; Female; Humans; Hysterectomy; Intestines; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence Local; Neoplasm Residual; Omentum; Ovarian Neoplasms; Ovariectomy; Peritoneum; Cytoreduction Surgical Procedures; Laparoscopy; Medicine (all); Obstetrics and GynecologyHysterectomy03 medical and health sciencesadjuvantlocalAppendectomyHumansSurvival rateFallopian TubesAgedHysterectomybusiness.industryAdvanced ovarian cancer interval debulking surgery laparoscopic cytoreduction minimally invasive surgery neoadjuvant chemotherapy quality of life adult aged 80 and over appendectomy chemotherapy adjuvant fallopian tubes feasibility studies female humans hysterectomy intestines middle aged neoadjuvant therapy neoplasm recurrence local neoplasm residual omentum ovarian neoplasms ovariectomy peritoneum cytoreduction surgical procedures laparoscopyPerioperativeneoplasm recurrenceSurgerySettore MED/40 - GINECOLOGIA E OSTETRICIAquality of lifeFeasibility StudiesLaparoscopyLymphadenectomyNeoplasm Recurrence LocalbusinessneoplasmAmerican Journal of Obstetrics and Gynecology
researchProduct

Clinical outcome of recurrent locally advanced cervical cancer (LACC) submitted to primary multimodality therapies

2015

Abstract Objectives Recurrence of disease represents a clinical challenge in cervical cancer patients, especially when all available treatment modalities have been used in the primary setting. The aim of this study was to analyze the patterns of recurrence and their association with clinical outcome in locally advanced cervical cancer (LACC) patients submitted to primary chemoradiation (CTRT) followed by radical surgery (RS). Methods This study was conducted on 364 LACC patients treated with CTRT plus RS since January 1996 to July 2012. For each relapse, information on date of clinical/pathological recurrence, and pattern of disease presentation were retrieved. Post-relapse survival (PRS) w…

OncologyAdultmedicine.medical_specialtyUterine Cervical Neoplasmrecurrent cervical cancerPrognosimedicine.medical_treatmentUterine Cervical NeoplasmsDiseaseObstetrics and gynaecologyRetrospective StudieInternal medicinemedicineHumansRadical surgeryChemoradiation; Post-relapse survival; Prognosis; Radical hysterectomy; Recurrent cervical cancer; Adult; Chemoradiotherapy; Adjuvant; Female; Humans; Neoadjuvant Therapy; Neoplasm Recurrence; Local; Retrospective Studies; Survival Analysis; Treatment Outcome; Uterine Cervical NeoplasmschemoradiationSurvival analysisNeoadjuvant therapyAdjuvantRetrospective StudiesSettore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIACervical cancerbusiness.industrypost-relapse survivalObstetrics and GynecologyRetrospective cohort studyChemoradiotherapy AdjuvantChemoradiotherapymedicine.diseaseSurvival AnalysisNeoadjuvant TherapySurgeryLog-rank testTreatment OutcomeNeoplasm RecurrenceSettore MED/40 - GINECOLOGIA E OSTETRICIAOncologyLocalradical hysterectomyFemaleSurvival AnalysiprognosisNeoplasm Recurrence LocalbusinessHuman
researchProduct

Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differ…

2012

The 1st St. Gallen EORTC Gastrointestinal Cancer Conference 2012 Expert Panel clearly differentiated treatment and staging recommendations for the various gastroesophageal cancers. For locally advanced gastric cancer (>= PT3N+), the preferred treatment modality was pre- and postoperative chemotherapy. The majority of panel members would also treat T2N+ or even T2N0 tumours with a similar approach mainly because pretherapeutic staging was considered highly unreliable. It was agreed that adenocarcinoma of the gastroesophageal junction (AEG) is classified best according to Siewert et al. Preoperative radiochemotherapy (RCT) is the preferred treatment for AEG type I and II tumours. For AEG type…

OncologyCancer Researchmedicine.medical_specialtyEsophageal Neoplasmspathology/surgery/therapymedicine.medical_treatmentAdenocarcinoma; pathology/surgery/therapy Carcinoma; Squamous Cell; pathology/surgery/therapy Chemoradiotherapy; Adjuvant Chemotherapy; Adjuvant Early Detection of Cancer Esophageal Neoplasms; pathology/surgery/therapy Esophagectomy Esophagogastric Junction; pathology/surgery Gastrectomy Humans Neoadjuvant Therapy Neoplasm Staging Predictive Value of Tests Stomach Neoplasms; pathology/surgery/therapy Treatment OutcomePredictive Value of TestAdenocarcinomaSDG 3 - Good Health and Well-beingPredictive Value of TestsStomach NeoplasmsGastrectomyStomach NeoplasmInternal medicineCarcinomamedicineHumansChemotherapyGastrointestinal cancerEsophageal NeoplasmLymph nodeAdjuvantEarly Detection of CancerNeoadjuvant therapyNeoplasm Stagingpathology/surgerybusiness.industryCarcinomaCancerChemoradiotherapy AdjuvantChemoradiotherapymedicine.diseaseNeoadjuvant TherapyEsophagectomyTreatment Outcomemedicine.anatomical_structureSquamous CellOncologyChemotherapy AdjuvantEsophagectomyCarcinoma Squamous CellAdenocarcinomaEsophagogastric JunctionbusinessChemoradiotherapyHuman
researchProduct

Positron emission tomography and neoadjuvant therapy of breast cancer

2011

The increasing use of neoadjuvant therapy for breast cancer has led to the development of early surrogate markers of response. Positron emission tomography (PET) allows noninvasive study of fundamental biologic processes in the tumor; furthermore, PET provides various markers to assess tumor response early in the course of therapy. Numerous studies have shown that changes in tumor glucose metabolism during therapy are significantly correlated with final response and patient outcome. Moreover, new PET tracers that are currently being developed or under evaluation, providing specific information on tumor characteristics or receptor expression, will assist the development of new targeted antic…

OncologyCancer Researchmedicine.medical_treatmentReceptor expressionTumor response030218 nuclear medicine & medical imaging[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicineAntineoplastic Agent0302 clinical medicineMonoclonalPet tracerHumanizedAdjuvantNeoadjuvant therapyComputingMilieux_MISCELLANEOUSAntibodies Monoclonal Humanized; Antineoplastic Agents; Biomarkers Tumor; Breast Neoplasms; Chemotherapy Adjuvant; Female; Fluorodeoxyglucose F18; Humans; Radiopharmaceuticals; Trastuzumab; Neoadjuvant Therapy; Positron-Emission Tomography; Cancer Research; Oncology; Medicine (all)Tumormedicine.diagnostic_testMedicine (all)General MedicineNeoadjuvant Therapy3. Good healthOncologyChemotherapy AdjuvantPositron emission tomography030220 oncology & carcinogenesisRadiopharmaceuticalFemaleBreast NeoplasmHumanmedicine.medical_specialtyAntineoplastic AgentsBreast Neoplasms[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineAntibodies Monoclonal HumanizedAntibodies[SDV.IB.MN] Life Sciences [q-bio]/Bioengineering/Nuclear medicine03 medical and health sciencesBreast cancerFluorodeoxyglucose F18Internal medicineBiomarkers TumormedicineChemotherapyHumansbusiness.industryTrastuzumabmedicine.diseasePositron-Emission TomographyRadiopharmaceuticalsbusinessBiomarkers
researchProduct

Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia.

2010

Abstract The clinical relevance of angiopoietin-2 (Ang2) in chronic lymphocytic leukemia (CLL) was previously suggested by the association between high Ang2, and shorter progression-free survival reported in small series of patients. Here, we evaluated Ang2 glycoprotein levels in plasma samples collected from a multicentric cohort of CLL patients (n = 316) using an enzyme-linked immunosorbent assay method, and we investigated its prognostic role in relation to time to first treatment (TTFT) and overall survival. Based on a cutoff equal to 2459 pg/mL, we divided our cohort in 2 subsets (high and low Ang2) composing 100 (31.6%) and 216 (68.4%) patients, respectively. High Ang2 was predictive …

glycoproteinMaleTime FactorsZAP-70Chronic lymphocytic leukemiavascular endothelial growth factor aBiochemistryGastroenterologyimmunoglobulin heavy chainsAdult Aged Aged; 80 and over Angiopoietin-2; analysis/blood Blood Chemical Analysis Female Humans Leukemia; Lymphocytic; Chronic; B-Cell; blood/diagnosis/mortality/therapy Male Middle Aged Neoadjuvant Therapy Prognosis Survival Analysis Time Factors Tumor Markers; Biological; bloodBlood plasma80 and overChronicTumor MarkersAged 80 and overLeukemiaHematologyHazard ratioprotein kinaseHematologyanalysis/bloodMiddle Agedchronic b-cell leukemiasPrognosisLymphocyticNeoadjuvant TherapyLeukemiaCohortFemaleAdultmedicine.medical_specialtyImmunologyangiopoietins chronic b-cell leukemias chronic lymphocytic leukemia plasma vascular endothelial growth factor a cd38 enzyme-linked immunosorbent assay glycoprotein immunoglobulin heavy chains protein kinaseNOcd38Angiopoietin-2bloodInternal medicinemedicineBiomarkers Tumorchronic lymphocytic leukemia angiopoietin-2.Humansbeta(2)-microglobulinplasmaSurvival analysisblood/diagnosis/mortality/therapyAgedbusiness.industryB-CellCell BiologyBiologicalmedicine.diseaseLeukemia Lymphocytic Chronic B-CellSurvival AnalysisConfidence intervalImmunologychronic lymphocytic leukemiaangiopoietin-2enzyme-linked immunosorbent assaybusinessCLL; angiopoietin-2; beta(2)-microglobulin; ZAP-70; CD38Settore MED/15 - Malattie del SangueangiopoietinsBlood Chemical AnalysisCLLCD38Blood Chemical Analysis; Angiopoietin-2; Humans; Neoadjuvant Therapy; Prognosis; Aged; Aged 80 and over; Leukemia Lymphocytic Chronic B-Cell; Adult; Middle Aged; Tumor Markers Biological; Time Factors; Female; Male; Survival Analysis
researchProduct

Minimally Invasive Approaches in Locally Advanced Cervical Cancer Patients Undergoing Radical Surgery After Chemoradiotherapy: A Propensity Score Ana…

2020

Abstract Purpose Chemoradiation (CT/RT) followed by radical surgery (RS) may play a role in locally advanced cervical cancer (LACC) patients with suboptimal response to CT/RT or in low-income countries with limited access to radiotherapy. Our aim is to evaluate oncological and surgical outcomes of minimally invasive radical surgery (MI-RS) compared with open radical surgery (O-RS). Patients and Methods Data for stage IB2–IVA cervical cancer patients managed by CT/RT and RS were retrospectively analyzed. Results Beginning with 686 patients, propensity score matching resulted in 462 cases (231 per group), balanced for FIGO stage, lymph node status, histotype, tumor grade, and clinical respons…

medicine.medical_specialtymedicine.medical_treatmentConcomitant Chemoradiation Neoadjuvant Chemotherapy Phase III Hysterectomy Radiation Therapy WomenUterine Cervical NeoplasmsHysterectomyDisease-Free Survival03 medical and health sciences0302 clinical medicinePhase IIIlocally advanced cervical cancer (LACC)locally advanced cervical cancerHumansMedicineWomenChemoradiotherapy; Disease-Free Survival; Female; Humans; Hysterectomy; Neoadjuvant Therapy; Neoplasm Recurrence Local; Neoplasm Staging; Propensity Score; Retrospective Studies; Uterine Cervical Neoplasms030212 general & internal medicineStage (cooking)Radical surgeryPropensity ScoreNeoadjuvant therapyNeoplasm StagingRetrospective StudiesCervical cancerHysterectomyRadiationbusiness.industrylocally advanced cervical cancer surgeryNeoadjuvant ChemotherapyRetrospective cohort studyChemoradiotherapyGynecologic Oncologymedicine.diseaseNeoadjuvant TherapySurgeryRadiation therapySettore MED/40 - GINECOLOGIA E OSTETRICIANeoplasm RecurrenceLocalOncology030220 oncology & carcinogenesisConcomitant ChemoradiationFemaleSurgeryTherapyNeoplasm Recurrence LocalbusinessChemoradiotherapy
researchProduct